Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2022, 31(2):107-111

What is new in patients with HFpEF?

Danková M, Gonçalvesová E
Kardiologická klinika LFUK a NÚSCH, a. s., Bratislava, Slovenská republika

Heart failure with preserved ejection fraction is common in the population of patients with heart failure syndrome and treatment is difficult. Whereas heart failure with a reduced ejection fraction can be treated with drugs that act to attenuate the overactivation of endogenous neurohormonal systems, therapeutic options for patients with heart failure and a preserved ejection fraction are limited. EMPERORPreserved (The Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction) was carried out to evaluate the effects of SGLT2 inhibition with empagliflozin on major heart failure outcomes. Treatment with empagliflozin significantly reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. This is the first evidence of efficacy of drug treatment for heart failure with preserved ejection fraction.

Keywords: heart failure; preserved ejection fraction; empagliflozin

Published: February 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Danková M, Gonçalvesová E. What is new in patients with HFpEF? Cardiology Letters. 2022;31(2):107-111.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;00:1-128. DOI:10.1093/eurheartj/ehab368 Go to original source...
    2. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (AD-HERE) Database. J Am Coll Cardiol 2006;47:76-84. DOI: 10.1016/j. jacc.2005.09.022. 4. Go to original source...
    3. Lam CS, Donal E, Kraigher-Krainer E, et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011;13:18-28. DOI: 10.1093/eurjhf/hfq121. 5. Go to original source...
    4. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, ther apies, and outcomes. Circulation 2012;126:65-75. DOI: 10.1161/CIRCULATIONAHA.111.080770. Go to original source...
    5. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: supplementary data. Eur Heart J 2021;00:1-42. doi:10.1093/eurheartj/ehab368 Go to original source...
    6. Omar W, Pandey A, Haykowsky MJ, Berry JD, Lavie CJ. The evolving role of cardiorespiratory fitness and exercise in prevention and management of heart failure. Curr Heart Fail Rep 2018;15:7580. Go to original source...
    7. Pabel S, Hamdani N, Singh J, et al. Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure with Preserved Fraction. Front. Physiol 2021;12:752370. doi.org/10.3389/fphys.2021.752370 Go to original source...
    8. Solomon SD, de Boer RA, DeMets D, et al. Dapagliflozin in heart failure with preserved and midly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail. 2021;23:1217-1225. doi: 10.1002/ejhf.2249 Go to original source...
    9. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with preserved ejection fraction. N Engl J Med 2021;385:14511461. DOI: 10.1056/NEJMoa2107038 Go to original source...
    10. Cleland JG, Tendera M, Adamus J, et al. The PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-2345. doi: 10.1093/eurheartj/ehl250 Go to original source...
    11. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359(23): 2456-2467. doi: 10.1056/NEJMoa0805450. Go to original source...
    12. Yusuf S, Pfeff er MA, Swedberg K, et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777781. doi: 10.1016/S0140-6736(03)14 285-7. Go to original source...
    13. Pitt B, Pffefer MA, Assman SF, et al. The TOPCAT Investigators Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 2014;370:1383-1392. doi: 10.1056/NEJMoa1313 731. Go to original source...
    14. Solomon SD, McMurray JJ, Anand IS, et al. The PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-1620. DOI: 10.1056/NEJMoa1908655. Go to original source...
    15. European Commission. Union Register of medicinal products for human use. Available at: https://ec.europa.eu/health/documents/community-register/html/h930.htm.

    Return to the content